FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2000460621> ?p ?o ?g. }

• W2000460621 endingPage "2626" @default.
• W2000460621 startingPage "2607" @default.
• W2000460621 abstract "Objective:A pharmacoeconomic analysis was performed to determine costs, consequences and cost effectiveness of a partially hydrolysed 100% whey-based infant formula, NAN HA, manufactured by Nestlé S.A, Switzerland (PHF-W) and branded under Nidal Excel HA in France, in the prevention of atopic dermatitis (AD) in ‘at risk’ children when compared to standard cows’ milk formula (SF) in France.Methods:A decision-analytic economic model depicting AD treatment pathways, as well as resource utilisation and costs associated with the treatment of AD in healthy yet ‘at risk’ French newborns who cannot be exclusively breastfed was constructed for a 12-month time horizon, including an initial 6 months of intervention with formula consumption. Model inputs were based on the literature, official formularies and expert opinion. The modelled treatment pathways included a dietary management approach (formula change), a medical treatment approach and a combination thereof. The final outcome was the expected cost per avoided case of AD, yielding an incremental cost per avoided case (ICER) of AD when comparing subjects who used PHF-W versus SF. Outcomes were presented from three perspectives: the French Ministry of Health (MOH), the subjects’ family and society as a whole. A secondary analysis also compared PHF-W to extensively hydrolysed formula (EHF) in prevention.Results:The number of avoided AD cases by selecting PHF-W over SF was 13 356 cases in a birth cohort of 185 298 ‘at risk’ infants. The base case analysis, at 65% reimbursement, yielded expected ICERs of €1343, € –624 (savings) and €719 from the MOH, family and societal perspectives, respectively. From all three perspectives, the highest cost was attributable to formula. In case of a 35% reimbursement rate for PHF-W, the ICER was €615 from the MOH perspective, while the use of PHF-W was cost neutral at 10% reimbursement. PHF-W was cost-saving against EHF (€98–€116 million savings depending on type of EHF), when this latter was used in prevention. One-way and probabilistic sensitivity analyses confirmed the robustness of the model.Conclusion:Under a certain range of assumptions, this analysis based on predictive modelling has established the cost effectiveness of PHF-W in the prevention of AD in infants." @default.
• W2000460621 created "2016-06-24" @default.
• W2000460621 creator A5008581830 @default.
• W2000460621 creator A5013876454 @default.
• W2000460621 creator A5023296155 @default.
• W2000460621 creator A5034132029 @default.
• W2000460621 creator A5039248236 @default.
• W2000460621 creator A5044762180 @default.
• W2000460621 creator A5078980402 @default.
• W2000460621 date "2010-10-06" @default.
• W2000460621 modified "2023-10-16" @default.
• W2000460621 title "Economic evaluation of a 100% whey-based, partially hydrolysed formula in the prevention of atopic dermatitis among French children" @default.
• W2000460621 cites W1776228394 @default.
• W2000460621 cites W1972217484 @default.
• W2000460621 cites W1983106797 @default.
• W2000460621 cites W1991796282 @default.
• W2000460621 cites W2003146643 @default.
• W2000460621 cites W2006677975 @default.
• W2000460621 cites W2008909342 @default.
• W2000460621 cites W2012685878 @default.
• W2000460621 cites W2016190330 @default.
• W2000460621 cites W2019237965 @default.
• W2000460621 cites W2023016774 @default.
• W2000460621 cites W2030360813 @default.
• W2000460621 cites W2071578690 @default.
• W2000460621 cites W2092068700 @default.
• W2000460621 cites W2101114210 @default.
• W2000460621 cites W2116158190 @default.
• W2000460621 cites W2124038769 @default.
• W2000460621 cites W2128144341 @default.
• W2000460621 cites W2134261811 @default.
• W2000460621 cites W2137278883 @default.
• W2000460621 cites W2143982789 @default.
• W2000460621 cites W2787533955 @default.
• W2000460621 cites W3125988286 @default.
• W2000460621 doi "https://doi.org/10.1185/03007995.2010.525472" @default.
• W2000460621 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20925454" @default.
• W2000460621 hasPublicationYear "2010" @default.
• W2000460621 type Work @default.
• W2000460621 sameAs 2000460621 @default.
• W2000460621 citedByCount "20" @default.
• W2000460621 countsByYear W20004606212012 @default.
• W2000460621 countsByYear W20004606212014 @default.
• W2000460621 countsByYear W20004606212015 @default.
• W2000460621 countsByYear W20004606212016 @default.
• W2000460621 countsByYear W20004606212017 @default.
• W2000460621 countsByYear W20004606212018 @default.
• W2000460621 countsByYear W20004606212019 @default.
• W2000460621 countsByYear W20004606212022 @default.
• W2000460621 crossrefType "journal-article" @default.
• W2000460621 hasAuthorship W2000460621A5008581830 @default.
• W2000460621 hasAuthorship W2000460621A5013876454 @default.
• W2000460621 hasAuthorship W2000460621A5023296155 @default.
• W2000460621 hasAuthorship W2000460621A5034132029 @default.
• W2000460621 hasAuthorship W2000460621A5039248236 @default.
• W2000460621 hasAuthorship W2000460621A5044762180 @default.
• W2000460621 hasAuthorship W2000460621A5078980402 @default.
• W2000460621 hasConcept C100406419 @default.
• W2000460621 hasConcept C138885662 @default.
• W2000460621 hasConcept C16005928 @default.
• W2000460621 hasConcept C160735492 @default.
• W2000460621 hasConcept C162324750 @default.
• W2000460621 hasConcept C187212893 @default.
• W2000460621 hasConcept C27206212 @default.
• W2000460621 hasConcept C2778329239 @default.
• W2000460621 hasConcept C2779150110 @default.
• W2000460621 hasConcept C2779703844 @default.
• W2000460621 hasConcept C50522688 @default.
• W2000460621 hasConcept C512399662 @default.
• W2000460621 hasConcept C521751864 @default.
• W2000460621 hasConcept C71924100 @default.
• W2000460621 hasConceptScore W2000460621C100406419 @default.
• W2000460621 hasConceptScore W2000460621C138885662 @default.
• W2000460621 hasConceptScore W2000460621C16005928 @default.
• W2000460621 hasConceptScore W2000460621C160735492 @default.
• W2000460621 hasConceptScore W2000460621C162324750 @default.
• W2000460621 hasConceptScore W2000460621C187212893 @default.
• W2000460621 hasConceptScore W2000460621C27206212 @default.
• W2000460621 hasConceptScore W2000460621C2778329239 @default.
• W2000460621 hasConceptScore W2000460621C2779150110 @default.
• W2000460621 hasConceptScore W2000460621C2779703844 @default.
• W2000460621 hasConceptScore W2000460621C50522688 @default.
• W2000460621 hasConceptScore W2000460621C512399662 @default.
• W2000460621 hasConceptScore W2000460621C521751864 @default.
• W2000460621 hasConceptScore W2000460621C71924100 @default.
• W2000460621 hasIssue "11" @default.
• W2000460621 hasLocation W20004606211 @default.
• W2000460621 hasLocation W20004606212 @default.
• W2000460621 hasOpenAccess W2000460621 @default.
• W2000460621 hasPrimaryLocation W20004606211 @default.
• W2000460621 hasRelatedWork W2003372003 @default.
• W2000460621 hasRelatedWork W2040968093 @default.
• W2000460621 hasRelatedWork W2069765531 @default.
• W2000460621 hasRelatedWork W2129009210 @default.
• W2000460621 hasRelatedWork W2398932897 @default.
• W2000460621 hasRelatedWork W2778253549 @default.
• W2000460621 hasRelatedWork W2806119138 @default.
• W2000460621 hasRelatedWork W2911778144 @default.

• next